FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response	: 0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Kummerfeld Keith C				2. Issuer Name and Ticker or Trading Symbol Arcturus Therapeutics Holdings Inc. [ARCT]					T (Che	Relationship of Reporting Person(s (Check all applicable) Director Officer (give title)			uer wner specify		
(Last) (First) (Middle) C/O ARCTURUS THERAPEUTICS HOLDINGS INC.				3. Date of Earliest Transaction (Month/Day/Year) 12/09/2022						X Officer (give title Other (specify below) See Remarks					
10628 SCIENCE CENTER DRIVE, SUITE 250				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) SAN DII	EGO C.	A	92121	_) Y		•	eporting Person	- 1
(City)	(S	tate)	(Zip)												
		Та	ble I - Non-D	erivati	ve Se	curities	Acq	uired, Di	sposed o	f, or Ben	eficially	Owned			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D			te	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) 5)		d (A) or : 3, 4 and	5. Amoun Securities Beneficia Owned Fo Reported	Forn lly (D) collowing (I) (Ir	. Ownership orm: Direct D) or Indirect) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code V	Amount	(A) or (D)	Price	Transacti (Instr. 3 a			IIIsu. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	Conversion Date Execution or Exercise (Month/Day/Year) if any		3A. Deemed Execution Date, if any (Month/Day/Year	4. Transa Code 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Employee Stock Option (right to buy)	\$16.92	12/09/2022		A		40,000 ⁽¹⁾		(2)	12/09/2032	Common Stock	40,000	\$0.00	40,000	D	

Explanation of Responses:

- 1. Represents options to purchase shares of common stock approved by the Board of Directors on December 9, 2022 pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as
- 2. The shares underlying this option vest 25% on December 9, 2023, the first anniversary of the date this award was approved by the Board of Directors, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

Remarks:

Vice President of Finance and Corporate Controller

/s/ Ilan Katz, attorney-in-fact 12/16/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.